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New cell types and cytokines have emerged as key participants in the elaboration of and recovery from
inflammation. A collection of reviews covers recent advances in our understanding of this crucial component
of host defense.‘‘There is no confusion like the
confusion of a simple mind.’’
—F. Scott Fitzgerald, The Great
Gatsby, 1925
Cytokines have come a long way since
the initial description of macrophage
inhibitory factor in the 1960s (David,
1966; Bloom and Bennett, 1966). For
years, immunologists marveled over the
potency of these molecules to push, pull,
and otherwise cajole a myriad of cells to
do just about anything in various 96-well
experimental settings. The therapeutic ad-
vances of anti-tumor necrosis factor (TNF)
therapies in chronic inflammatory bowel
and joint diseases and of interferon-
a (IFN-a) in multiple sclerosis and hepatitis
C virus infection moved the field beyond
the broadband approaches epitomized
by the use of steroids and broad-acting
immunosuppressives, however, and de-
monstrated that more precise targeting
of the immune system was possible.
Here, understanding the language of the
cytokines will be imperative. Various col-
ony-stimulating factors have been ex-
ploited for bone marrow reconstitution
(not without their own toxicities), but oth-
erwise the staggering multiplicity of ac-
tions has cut short the broad use of these
agents in human disease. Most of the cy-
tokines exist within multiple family mem-
bers and share combinatorial subunits
and/or receptor-recognition modules,
suggesting that evolution likes these
things but also that nuanced differences
probably exist among closely related fam-
ily members and that these must be rec-
ognized before the potential therapeutic
uses of these cytokines can be optimized.
As updated by Scheinecker et al. among
the series of reviews that follow, therapeu-
tic targeting of interleukin-1 (IL-1), IL-6,
and additional biomodulators extendsthe pharmacopoeia of immune intervention
in inflammatory diseases, but precisely
how to organize the rational approach for
the use of anticytokine therapies remains
too often empiric (Scheinecker et al.
[2008], this issue of Immunity).
The series of review articles in this issue
address recent subjects of much currency
in the cytokine field. Of note, the discov-
ery of additional CD4+ T cell subsets that
round out the canonical T helper 1 (Th1)
and Th2 cell subsets first described in
the 1980s emerges as a constant theme
(Figure 1). Because of their capacity to be-
come long-lived memory effector cells,
these various populations of helper T cells
can underpin many chronic inflammatory
states mediated by cytokines when left
unregulated. The Th1 and Th2 paradigm
drove substantial discoveries in the
immune system, perhaps most impor-
tantly the linking of epigenetic alterations
at sites of expressed cytokines with
canonical ‘‘master transcriptional regula-
tors’’ whose binding could drive cell-fate
decisions, thus providing a mechanism
by which gene expression and cellular
functions become stabilized (reviewed in
Ansel et al., 2006; Lee et al., 2006). These
findings in turn were driven by a quiet
revolution in immunology. Over the past
20 years, 96-well-plate experiments
were replaced by challenges using patho-
gens of every sort to tweak living animals
in order to probe the functions of cells
and, indirectly, the cytokines they se-
creted, in vivo. A slew of model organisms
on defined genetic backgrounds became
established, such that today’s second-
year immunology graduate students are
quite conversant in experiments with
LCMV, Listeria, helminthes, and protozoa.
Close behind were autoimmune models
of every organ. Once these models were
in hand, investigators cooked up a myriadImmof lineage- and function-marking mice
that could reveal cell fate and/or function
in vivo, and, with that, the age of im-
munobiology expanded tremendously.
Some of the fruits of those studies have
been comprehensively summarized in
the following reviews.
Two reviews in this issue, by Ouyang
et al. (2008) and McGeachy and Cua
(2008), outline in detail the discovery,
function, and characterization of Th17
cells, including their potential role in the
maintenance of barrier homeostasis in
response to epithelial injury but also in
the mediation of chronic inflammatory
syndromes. Initially implicated by their
dysregulated appearance in murine mo-
dels of inflammatory diseases, includ-
ing experimental autoimmune encepha-
lomyelitis and antigen-induced arthritis,
Th17 cells have gained favor with their
capacity to restrict infections due to vari-
ous extracellular bacteria and fungi. As
covered in the reviews that follow, this
has a certain credence, given that IL-17A
and IL-17F, major cytokines produced
by Th17 cells, induce granulocytopoiesis
and CXC chemokines that together drive
the accumulation of myeloid cells in
tissues. The capacity of IL-22, a cytokine
expressed by Th17 cells, to activate epi-
thelial repair and defense responses sug-
gests the working hypothesis that IL-22
plugs the holes in the barrier while IL-17
calls in the neutrophils to clean up the
mess. In the mouse, problems seem to
arise when Th17 cells get activated in
closed spaces, such as in joints and in
the brain, where neutrophils cannot be
so readily disposed of. As addressed in
both reviews, IL-17 and Th17 cells have
been observed at the scene of the crime
in diverse inflammatory syndromes in
humans, including psoriasis, multiple
sclerosis, asthma, and inflammatoryunity 28, April 2008 ª2008 Elsevier Inc. 437
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CommentaryFigure 1. CD4+ T Helper Cell Subsets Orchestrate Inflammation and its Regulation
CD4+ T cells in peripheral lymphoid tissues can adopt multiple cell fates that regulate inflammation. Some
of the cytokines and other factors that have been associated with induction of each subset are indicated,
although their roles in vivo remain incompletely defined. Each subset makes a canonical group of cyto-
kines that act on other cells to drive interactions of each subset with other immune cells often found in
close association. The capacity for memory allows T helper cell subsets to mediate chronic inflammatory
states when not regulated.
Abbreviations are as follows: CTL, cytotoxic T cells; iTreg, inducible T regulatory cells; LT, lymphotoxin;
PMN, polymorphonuclear neutrophils; Tfh, T follicular helper cells; TiPDCs, TNF- and iNOS-producing
dendritic cells; TSLP, thymic stromal lymphopoietin.bowel disease. Mutations in the receptor
for IL-23, a cytokine that sustains the
actions of Th17 cells in vivo, have been
associated with altered risks for inflamma-
tory bowel disease, psoriasis, and autoim-
mune thyroiditis. Details remain incom-
plete, including the particulars regarding
whether the same factors are necessary
in mouse and human for generation of
Th17 cells and exactly which cell types
contribute IL-17 under diverse conditions,
but the associations of these cells with
a multitude of inflammatory syndromes
seems well established.
Inflammation demands regulation. As
reviewed in this issue by Li and Flavell
(2008), transforming growth factor-b
(TGF-b) and IL-10 figure prominently in
immunoregulation, as revealed years
ago by the spontaneous inflammatory438 Immunity 28, April 2008 ª2008 Elseviersyndromes that erupt when either is
deleted in the mouse. TGF-b is a requisite
growth factor for FoxP3+ T regulatory
(Treg) cells, and the inflammation that
arises in TGF-b null mice can be largely
explained by the absence of these cells.
TGF-b exists in a latent pro-form in tis-
sues, where it can be activated by avb8
integrin on tissue dendritic cells (DCs) to
sustain Treg, as best worked out in the
lamina propria of the small bowel (Travis
et al., 2007). So how do we activate the
immune system if Treg cells are always
in play? When Toll-like receptor ligands
or inflammatory cytokines activate tissue
macrophages, DCs, and epithelia, IL-6 is
released, and the combination of TGF-b
and IL-6 promotes the differentiation of
Th17 cells. Intriguingly, the source of the
TGF-b is T cells, probably Tregs them-Inc.selves, suggesting an intimate dance
between suppressor and inflammatory T
cells that has been borne out by their
close functional relationship during differ-
entiation (Bettelli et al., 2006). Yet addi-
tional layers of regulation exist, and the
addition of IL-27, which is made by DCs,
with TGF-b and IL-6, leads to the elabora-
tion of IL-10 from T cells, which, as re-
viewed by O’Shea and Murray, activates
a potent anti-inflammatory program via
Stat3 that includes induction of Socs3,
a negative regulator of cytokine-receptor
signaling. The complex layering of signals
relayed by the module of Stat3 and Socs 3
hints at further regulatory nuances in the
cell that exist to deconvolute cytokine-
rich environments within the nucleus of
individual cells but that ultimately deter-
mine how inflammatory responses are
curtailed and homeostasis is recovered
(O’Shea and Murray [2008], this issue).
As shown in the accompanying figure,
alternative fates can await the helper T
cell, although many remained incom-
pletely defined as compared to the now-
canonical Th1, Th2, Th17, and inducible
Treg cells. The identification of ‘‘mas-
ter regulators’’ for these cells—Tbet,
GATA3, RORgt and RORa, and FoxP3,
respectively—led to the use of reagents
critical for the more complete under-
standing of their roles in immunity. T follic-
ular helper (Tfh) cells mediate the germi-
nal-center reaction, and understanding
of the factors that drive their selection
and differentiation could greatly aid the
ability to make high-affinity antibody re-
sponses and long-lived memory B cells
(King et al., 2008). Questions remain
about the relationships of Tfh cells to ca-
nonical cytokine-expressing subsets, in-
cluding the role of IL-21, which is a critical
marker for Tfh cells yet also performs an
autocrine function in the promotion of
Th17 cell development. Despite their
association with peripheral purulent
inflammation, Th17 cells have been impli-
cated in germinal-center reactions, an
area that requires more study to be put
into biologic perspective (Hsu et al.,
2008). MicroRNAs (miR), as in other
tissues, undoubtedly play a role in T
helper cell subset development, and an
unusual wrinkle has been shown with Tfh
cells. In following up a mutation that re-
vealed exuberant Tfh development and
autoimmunity, Goodnow, Vinuesa and
colleagues demonstrated that Roquin
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miR-101 to target the inducible costimula-
tor (ICOS) mRNA for degradation, thus
limiting Tfh development and adding fur-
ther complexity to the issue of regulation
(Yu et al., 2007). Antibodies undoubtedly
contribute to many chronic inflammatory
syndromes, and understanding of the fac-
tors that regulate Tfh cell versus alterna-
tive T helper cell fate decisions will be an
important area for further inquiry. Addi-
tional cell types, including IL-10-produc-
ing Tr1 cells and TGF-b-producing Th3
cells, await clarification via molecular elu-
cidation of their lineage, localization, and
stability in vivo.
Inescapable in this collection of infor-
mative and up-to-date reviews is the
explosion of information regarding the
IL-20s. Although not all are touched
upon here, each has revealed an excep-
tionally rich biology that is suggestive of
the Roaring ‘20s of American history,
a time of unprecedented exploration,
expansion, individualism, and creativity.
Several, including IL-20, IL-22, IL-24,
and IL-26, are members (with IL-10 and
IL-19) of the IL-10 family of cytokines.
Many of these cytokines have already
been implicated in epithelial inflammatory
syndromes in humans, such as psoriasis,
although whether these serve to limit in-
flammation or promote it awaits further
study, as conflicting information, as noted
in the accompanying reviews, is apparent
from the initial mouse experiments. The
gene encoding IL-26, a prominent part of
the human Th17 cell-derived cytokine
repertoire, sits in a linked expression array
with the genes encoding IL-22 and IFN-g,
although it has been disrupted by a long
interspersed nuclear element insertion in
the mouse. The mechanisms that regulate
expression of this collection of genes
have only begun to be probed (Schoen-
born et al., 2007), but will likely bear simi-
larities with the extensively mined Th2
cytokine locus comprising the genes en-
coding IL-4, IL-5, and IL-13. Indeed, core-
gulation of IFN-g and IL-22 in CD4+ T cells
by the transmembrane protein class I
MHC-restricted T cell-associated mole-cule (Crtam) was recently demonstrated,
thus creating an entry into the mecha-
nisms for coordinately accessing this lo-
cus (Yeh et al., 2008).
The IL-10 family is itself an extension of
the interferon family, in which IL-28 and IL-
29 (as well as the type 1 interferons and
IFN-g) have been identified as additional
members (Sheppard et al., 2003). These
unusual interferons figure in antiviral re-
sponses, but only few studies address
their additional functions in innate immu-
nity. As compared to other IFNs, IL-28
and IL-29 bind a distinct receptor made
up of the type 1 IFNR1 and the IL10R2,
suggesting that novel activities will be
mediated.
Two members of the IL-12 family (which
also includes IL-12 and IL-35) are present
in the roaring ‘20s, including IL-23, which
is critical in Th17 cell maintenance in vivo
and in the induction of IL-22; and IL-27,
which has been implicated in the induc-
tion of IL-10 (Stumhofer et al., 2007).
Rounding out the ‘20s are IL-21, a gc-us-
ing IL-2-family member involved in Tfh
and Th17 cell function, and IL-25 (struc-
turally a member of the IL-17 family), a po-
tent inducer of IL-4- and IL-13-mediated
immunity when administered to mice
(Fort et al., 2001). In short, the ‘20s repre-
sent a remarkably potent cytokine decade
with great potential to teach us much
about immune cell activation and regula-
tion and from which, hopefully, novel ther-
apeutics might be harnessed for inflam-
matory diseases of humans.
In American history, the lack of regula-
tion in the 1920s resulted in an inevitable
financial and social meltdown (encapsu-
lated so well in Fitzgerald’s great novel)
that resulted in the Great Depression
and the hammering out of regulatory
networks that survive to this day. Thank-
fully, evolution has already settled the reg-
ulation of the roaring ‘20s in immunology,
and, as revealed in this special issue of
Immunity, we have begun to glean some
hints toward understanding the cro-
ssregulation among these diverse and
powerful molecules. The comprehensive
reviews that follow begin the clarification.ImmREFERENCES
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